Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks
Question
Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks
Direct answer
Pipeline clinical setbacks across pelacarsen and eplontersen reduce discounted long-term milestone cash flows, compressing IONS market capitalization. — bearish pressure on IONS via clinical pipeline NPV write-down and milestone cash flow contraction.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-21
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks”, revision 1, evidence through 2026-09-21. https://marketontology.com/catalysts/2026-09-21/ionis-pharmaceuticals-trades-down-40-following-late-stage-clinical-setbacks-df2a66
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| IONS | ▼Bear | 1–3 months | clinical pipeline NPV write-down and milestone cash flow contraction | 75 |
Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks
Pipeline clinical setbacks across pelacarsen and eplontersen reduce discounted long-term milestone cash flows, compressing IONS market capitalization. — bearish pressure on IONS via clinical pipeline NPV write-down and milestone cash flow contraction.
Stock dropped over 40% year-to-date on pelacarsen and eplontersen pipeline failures.
- SourceStock dropped over 40% year-to-date on pelacarsen and eplontersen pipeline failures.
- TransmissionPipeline clinical setbacks across pelacarsen and eplontersen reduce discounted long-term milestone cash flows, compressing IONS market capitalization.
- SummaryIonis Pharmaceuticals has dropped over 40% this year on late-stage trial failures. Programs impacted include key drug candidates pelacarsen and eplontersen. Wall Street maintains an $83.82 consensus target based on remaining ASO platform assets.
- IONSDirect directional or hedged short
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Fed officials or competing data may reframe the print
- IONS closes above pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- IONS price vs. pre-event level
- IONS volume vs. 20-day average
- 2Y/10Y Treasury yield direction
- DXY direction
- Fed funds futures repricing
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| IONS | Bearishdisagreed | 44.90 2026-09-21 | +1.89% | +1.49% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook · Polygon News · 2026-09-20
Related catalysts
- 2026-09-24Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN ProgramsIONS+1.57%
- 2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney DiseaseAZN IONS+1.57%
- 2026-09-24Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney diseaseIONS+1.57%
- 2026-09-24Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy TherapiesIONS+1.57%
- 2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney DiseaseAZN IONS+1.57%
- 2026-09-24Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney diseaseIONS+1.57%
- 2026-09-24Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy TherapiesIONS+1.57%
- 2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney DiseaseAZN IONS+1.57%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.